The European Commission approved Dupixent (dupilumab) for moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years with inadequate response to prior therapy. The approval expands the drug's label in a pediatric population and is a positive regulatory catalyst for Regeneron and Sanofi. The news is favorable for the companies but likely has limited broader market impact.
The European Commission approved Dupixent (dupilumab) for moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years with inadequate response to prior therapy. The approval expands the drug's label in a pediatric population and is a positive regulatory catalyst for Regeneron and Sanofi. The news is favorable for the companies but likely has limited broader market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.70
Ticker Sentiment
